Immediate Impact

1 from Science/Nature 56 standout
Sub-graph 1 of 25

Citing Papers

Advances in cancer immunotherapy: historical perspectives, current developments, and future directions
2025 Standout
TET (Ten-eleven translocation) family proteins: structure, biological functions and applications
2023 Standout
2 intermediate papers

Works of Bernhard J. Woermann being referenced

Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA
2018
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)
2008

Author Peers

Author Last Decade Papers Cites
Bernhard J. Woermann 324 174 210 21 462
Nils Winkelmann 276 234 285 18 553
Kristina Vermaelen 408 173 194 15 538
Eva Arranz 247 163 167 24 537
Patricia Martin‐Regueira 318 103 197 20 444
Koorosh Korfi 237 219 148 17 526
Dominique Mühlematter 359 209 157 25 520
RT Silver 344 148 277 13 575
J. W. G. Janssen 269 233 126 18 549
JM Hernández 343 184 100 12 423
Gerlinde Mitterbauer‐Hohendanner 320 85 211 20 516

All Works

Loading papers...

Rankless by CCL
2026